Capital DailyCapital Daily
Markets · Investing · Business
Capital DailyCapital Daily
Finance

AbbVie Stock: Buy, Sell, or Hold in October?

The pharmaceutical giant still looks like a stable long-term investment.

AbbVie Stock: Buy, Sell, or Hold in October?

Published September 30, 2026 · Category: Finance

Overview

AbbVie (NYSE: ABBV), one of the world's largest pharmaceutical companies, has been a reliable long-term investment. It's raised its dividend annually for 53 consecutive years, making it a Dividend King that has increased its payout for at least 50 years in a row, and a dozen of its drugs generate more than $1 billion in annual revenue. But as the 10-year Treasury yield stays above 5% -- its highest level since 2007 -- is it still smart to buy and hold this dividend stock?

Image source: Getty Images.

In 2023, AbbVie lost its U.S. patent exclusivity for Humira, the blockbuster autoimmune drug that once accounted for over 60% of its sales.

Details

Continue reading

Source

Originally published at www.fool.com.

Related Articles

CD
Capital Daily Newsroom

Capital Daily covers markets, crypto and commodities for Asia & the Middle East — tier-1 desk research, AI-driven analysis, institutional-grade data. Tip our newsroom: [email protected]

Email the newsroom →
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.